Savara Inc (SVRA) Stock Profile — Insider Trades & Financials

Net Income-$32.2M

EPS$-0.40

Market Cap$1.2B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Matthew Pauls

CEO & Executive Director

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The companyâs lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Founded: 2007
Employees: 70
Headquarters: Langhorne, Pennsylvania, United States
Website

⚡

Core Efficiency

ROE?

-15.87%

ROA?

-12.72%

D/E Ratio?

0.25

📊

Profitability Ratios

Current Ratio?

11.85

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 12, 2026 (in 125 days)

Annual Report (10-K) — Based on filing pattern

Aug 12, 2026

Predicted10-K

Mar 13, 2026

10-KQ4 20250d after period end

Nov 12, 2025

10-QQ3 20250d after period end

Aug 13, 2025

10-QQ2 20250d after period end

May 13, 2025

10-QQ1 20250d after period end

Apr 25, 2025

10-K/AQ4 202429d after period end

Nov 12, 2024

10-QQ3 20245d after period end

Aug 12, 2024

10-QQ2 20244d after period end

May 9, 2024

10-QQ1 20240d after period end

Loading company sections...

Savara Inc

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness